Clinical trials: Cirrhosis Portal
Hepatic Impairment
A Single and Repeat Dose Trial in Participants With Hepatic Impairment
This study is a a single (open-label) and repeat dose (randomised, placebo controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh…
- Trial name
- NCT05009680
- Testing
- GB1211
- Where
- 4 sites in Bulgaria
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Hepatic Impairment
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
This multiple-center, nonrandomized, open label, parallel group, single dose study will be conducted in male and female subjects with normal hepatic function or moderate (Child-Pugh Class B) hepatic impairment to evaluate the…
- Trial name
- NCT02581592
- Testing
- TD-4208
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Mylan Inc.
Liver Pathology
Screening of Patients With Hepatic Fibrosis or Cirrhosis B and C
Regardless of its etiology (chronic hepatitis B or C, alcohol consumption, metabolic steatohepatitis, hemochromatosis, autoimmune liver disease), cirrhosis is a real public health issue.
- Trial name
- DEP-CB (NCT06755632)
- Testing
- TROD (rapid diagnostic orientation test) and FibroScan®
- Where
- 2 sites in France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cirrhosis
Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics
The three objectives of this trial are: 1. To demonstrate that a decline in hepatic metabolic function as measured by BreathID will correlate with changes in CTP and MELD scores in patients with cirrhosis. 2.
- Trial name
- NCT00375011
- Where
- 3 sites in United States, Israel
- Volunteers
- 200 people
- Sponsor
- Meridian Bioscience, Inc.
Portal Hypertension, Clinically Significant Portal Hypertension
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be…
- Trial name
- NCT03436550
- Testing
- mpMRI, ARFI US
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Quality of Life, the Incidence of Whole Complications Resultant From Decompensated Liver
Statin Impact on Hepatic Decompensation
The study aims to evaluate the impact of statin on hepatic decompensation.
- Trial name
- NCT05563389
- Testing
- Atorvastatin 20mg
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Cirrhosis
EYE-Mobile TRACKer IN the Diagnosis of Minimal Hepatic Encephalopathy
Hepatic encephalopathy (HE) corresponds to the neurological or the neuropsychological symptoms caused by an acute or chronic liver disease and/or porto-systemic shunt.
- Trial name
- EyeMTRACKIN-HE (NCT03732118)
- Testing
- Eye-tracker Mobile EBT
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Esophageal Neoplasms, Cirrhosis
Endoscopic Resection of Early Esophageal Tumors in the Context of Cirrhosis or Portal Hypertension
Cirrhotic patients may be at high risk for esophageal cancer. Endoscopic resection is the standard treatment for superficial tumors.
- Conditions
- Esophageal Neoplasms, Cirrhosis, Portal Hypertension
- Trial name
- NCT04994548
- Testing
- Endosocpic resection of early esophageal tumor
- Volunteers
- 112 people
- Sponsor
- Central Hospital, Nancy, France
Liver Cirrhosis, HCC - Hepatocellular Carcinoma
Effect of Laparoscopic Hepatectomy Combined With Splenectomy on Hepatic Functional Reserve and Immune Function
Splenectomy may relieve hypersplenism, reverse liver fibrosis, improve hepatic functional reserve, and reshape the systemic antitumor immune milieu by removing the source of negative immunomodulation.
- Conditions
- Liver Cirrhosis, HCC - Hepatocellular Carcinoma, Hypersplenism
- Trial name
- LHCS-HFRI (NCT07811687)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Liver Cirrhosis, Hepatic Encephalopathy
Diagnosis of Covert/Minimal Hepatic Encephalopathy by Means of Continuous Reaction Time Measurement
The investigators wish to investigate how the Continuous Reaction Time (CRT) method can be used in the diagnosis and monitoring of covert hepatic encephalopathy (cHE)in patients with cirrhosis of the liver.
- Trial name
- NCT01773538
- Testing
- Lactulose and rifaximin, Branched Chain amino acids
- Where
- 2 sites in Denmark
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Mette Munk Lauridsen
Liver Fibrosis, Liver Fibrosis in Chronic Hepatitis B
A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.
This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy.
- Trial name
- NCT07412236
- Testing
- Hydronidone (270mg)
- Where
- China
- Volunteers
- 1,208 people
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Iron Deficiency Anemia, Chronic Liver Failure
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease.
- Trial name
- NCT04335058
- Testing
- Lactoferrin + Iron Supplement, Iron Supplement
- Where
- India
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Cirrhosis, Liver
Acute-On-Chronic Liver Failure In Cirrhotic Patients
Cirrhosis is a condition characterized by diffuse fibrosis, severe disruption of the intrahepatic arterial and venous flow, portal hypertension and, ultimately, liver cell failure.
- Trial name
- NCT04790435
- Where
- Egypt
- Volunteers
- 109 people
- Sponsor
- Sohag University
Alcoholic Liver Cirrhosis
Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC
This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.
- Trial name
- NCT03838250
- Testing
- Cellgram™ (Bone marrow-derived MSCs)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Pharmicell Co., Ltd.
Liver Cirrhosis
Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis
the study includes patients with liver cirrhosis irrespective of the stage excluding people with active tumor or other major health issue endangering life, the protocol includes the use of autologous bone marrow derived…
- Trial name
- bone marrow (NCT07374185)
- Testing
- Autologous Bone Marrow Aspirate Concentrate
- Where
- Iraq
- Volunteers
- 10 people
- Sponsor
- Global Stem Cell Center, Baghdad
Portal Hypertension, Chronic Liver Disease
EUS vs TJ for Liver Biopsy and Portal Pressure Gradient Measurement
This study will directly compare the endoscopic ultrasound guided approach to obtain adequate liver biopsies and portal pressure gradient measurements to the current standard of care which uses the transjugular approach.
- Conditions
- Portal Hypertension, Chronic Liver Disease, Cirrhosis
- Trial name
- NCT05118308
- Testing
- Transjugular hepatic venous pressure gradient measurement with liver biopsy, Endoscopic ultrasound portal pressure gradient measurement with liver biopsy
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Portal Hypertension, Chronic Liver Disease
Within-Session Repeatability of EUS-Guided Portal Pressure Gradient Measurement
This prospective multicentre observational reliability study will determine how much a repeated endoscopic ultrasound-guided portal pressure gradient (EUS-PPG) measurement differs from the first measurement in the same patient…
- Conditions
- Portal Hypertension, Chronic Liver Disease, Liver Cirrhosis
- Trial name
- REPEAT-PPG (NCT07877298)
- Testing
- Repeated EUS-Guided Portal Pressure Gradient Measurement
- Where
- 5 sites in Belgium, Canada and 2 more
- Volunteers
- 150 people
- Sponsor
- University Hospital Muenster
Cirrhosis Portal
Incidence of Diabetes and Metabolic Disorders After TIPS in Cirrhotic Patients
Decompensated cirrhosis is associated with sarcopenia. TIPS is an efficient treatment of portal hypertension. Based on our retrospective data, TIPS induces in 30% of cirrhotic patients metabolic disorders associated with diabetes…
- Trial name
- Gluco-TIPS (NCT04387058)
- Testing
- TIPS
- Where
- France
- Volunteers
- 111 people
- Sponsor
- University Hospital, Toulouse
Liver Cirrhoses, Portal Hypertension Related to Cirrhosis
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease
Cirrhosis is a form of advanced liver disease that can lead to serious complications, especially when combined with severe obesity.
- Conditions
- Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity, TIPS
- Trial name
- OPTIMAL (NCT07058155)
- Testing
- Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect)
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- The Cleveland Clinic
Acute on Chronic Hepatic Failure
Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units
Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate.
- Trial name
- HEPATICUS-1 (NCT01079091)
- Testing
- ADVOS (Hepa Wash), Standard Medical Therapy
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- Hepa Wash GmbH